ID   LYN_HUMAN               Reviewed;         512 AA.
AC   P07948; A0AVQ5;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   12-OCT-2022, entry version 252.
DE   RecName: Full=Tyrosine-protein kinase Lyn;
DE            EC=2.7.10.2;
DE   AltName: Full=Lck/Yes-related novel protein tyrosine kinase;
DE   AltName: Full=V-yes-1 Yamaguchi sarcoma viral related oncogene homolog;
DE   AltName: Full=p53Lyn;
DE   AltName: Full=p56Lyn;
GN   Name=LYN; Synonyms=JTK8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RX   PubMed=3561390; DOI=10.1128/mcb.7.1.237-243.1987;
RA   Yamanashi Y., Fukushige S., Semba K., Sukegawa J., Miyajima N.,
RA   Matsubara K., Yamamoto T., Toyoshima K.;
RT   "The yes-related cellular gene lyn encodes a possible tyrosine kinase
RT   similar to p56lck.";
RL   Mol. Cell. Biol. 7:237-243(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RX   PubMed=8125304; DOI=10.1016/0378-1119(94)90811-7;
RA   Rider L.G., Raben N., Miller L., Jelsema C.;
RT   "The cDNAs encoding two forms of the LYN protein tyrosine kinase are
RT   expressed in rat mast cells and human myeloid cells.";
RL   Gene 138:219-222(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 369-424.
RX   PubMed=2247464; DOI=10.1073/pnas.87.22.8913;
RA   Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.;
RT   "Putative tyrosine kinases expressed in K-562 human leukemia cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 369-424.
RX   PubMed=1510669; DOI=10.1016/s0006-291x(05)81562-1;
RA   Bielke W., Ziemiecki A., Kappos L., Miescher G.C.;
RT   "Expression of the B cell-associated tyrosine kinase gene Lyn in primary
RT   neuroblastoma tumours and its modulation during the differentiation of
RT   neuroblastoma cell lines.";
RL   Biochem. Biophys. Res. Commun. 186:1403-1409(1992).
RN   [6]
RP   FUNCTION IN CD19 PHOSPHORYLATION, AND INTERACTION WITH CD19.
RX   PubMed=7687428; DOI=10.1006/bbrc.1993.1807;
RA   Roifman C.M., Ke S.;
RT   "CD19 is a substrate of the antigen receptor-associated protein tyrosine
RT   kinase in human B cells.";
RL   Biochem. Biophys. Res. Commun. 194:222-225(1993).
RN   [7]
RP   CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND INTERACTION WITH HCLS1.
RX   PubMed=7682714; DOI=10.1073/pnas.90.8.3631;
RA   Yamanashi Y., Okada M., Semba T., Yamori T., Umemori H., Tsunasawa S.,
RA   Toyoshima K., Kitamura D., Watanabe T., Yamamoto T.;
RT   "Identification of HS1 protein as a major substrate of protein-tyrosine
RT   kinase(s) upon B-cell antigen receptor-mediated signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:3631-3635(1993).
RN   [8]
RP   INTERACTION WITH FCGR1A, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, AND
RP   PHOSPHORYLATION.
RX   PubMed=8064233; DOI=10.1084/jem.180.3.1165;
RA   Wang A.V., Scholl P.R., Geha R.S.;
RT   "Physical and functional association of the high affinity immunoglobulin G
RT   receptor (Fc gamma RI) with the kinases Hck and Lyn.";
RL   J. Exp. Med. 180:1165-1170(1994).
RN   [9]
RP   PHOSPHORYLATION AT TYR-397 AND TYR-508, AND ACTIVITY REGULATION.
RX   PubMed=7935444; DOI=10.1128/mcb.14.11.7306-7313.1994;
RA   Hata A., Sabe H., Kurosaki T., Takata M., Hanafusa H.;
RT   "Functional analysis of Csk in signal transduction through the B-cell
RT   antigen receptor.";
RL   Mol. Cell. Biol. 14:7306-7313(1994).
RN   [10]
RP   INTERACTION WITH EPSTEIN-BARR VIRUS LMP2A (MICROBIAL INFECTION).
RX   PubMed=7895172; DOI=10.1016/s1074-7613(95)80040-9;
RA   Miller C.L., Burkhardt A.L., Lee J.H., Stealey B., Longnecker R.,
RA   Bolen J.B., Kieff E.;
RT   "Integral membrane protein 2 of Epstein-Barr virus regulates reactivation
RT   from latency through dominant negative effects on protein-tyrosine
RT   kinases.";
RL   Immunity 2:155-166(1995).
RN   [11]
RP   PHOSPHORYLATION AT TYR-508 BY MATK.
RC   TISSUE=Platelet;
RX   PubMed=9171348; DOI=10.1093/emboj/16.9.2342;
RA   Hirao A., Hamaguchi I., Suda T., Yamaguchi N.;
RT   "Translocation of the Csk homologous kinase (Chk/Hyl) controls activity of
RT   CD36-anchored Lyn tyrosine kinase in thrombin-stimulated platelets.";
RL   EMBO J. 16:2342-2351(1997).
RN   [12]
RP   FUNCTION, INTERACTION WITH NEDD9 AND BCAR1, AND PHOSPHORYLATION.
RX   PubMed=9020138; DOI=10.1074/jbc.272.7.4230;
RA   Manie S.N., Beck A.R.P., Astier A., Law S.F., Canty T., Hirai H.,
RA   Druker B.J., Avraham H., Haghayeghi N., Sattler M., Salgia R.,
RA   Griffin J.D., Golemis E.A., Freedman A.S.;
RT   "Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein,
RT   in a cytoskeleton-dependent signaling pathway initiated by ligation of
RT   integrin or antigen receptor on human B cells.";
RL   J. Biol. Chem. 272:4230-4236(1997).
RN   [13]
RP   INTERACTION WITH FCGR2B.
RX   PubMed=9232445; DOI=10.1016/s0165-2478(97)00055-2;
RA   Sarmay G., Koncz G., Pecht I., Gergely J.;
RT   "Fc gamma receptor type IIb induced recruitment of inositol and protein
RT   phosphatases to the signal transductory complex of human B-cell.";
RL   Immunol. Lett. 57:159-164(1997).
RN   [14]
RP   INTERACTION WITH KIT, AND PHOSPHORYLATION.
RX   PubMed=9341198; DOI=10.1074/jbc.272.43.27450;
RA   Linnekin D., DeBerry C.S., Mou S.;
RT   "Lyn associates with the juxtamembrane region of c-Kit and is activated by
RT   stem cell factor in hematopoietic cell lines and normal progenitor cells.";
RL   J. Biol. Chem. 272:27450-27455(1997).
RN   [15]
RP   FUNCTION IN DNA DAMAGE RESPONSE; APOPTOSIS AND PHOSPHORYLATION OF
RP   PTPN6/SHPTP1, AND INTERACTION WITH PTPN6/SHPTP1.
RX   PubMed=10574931; DOI=10.1074/jbc.274.49.34663;
RA   Yoshida K., Kharbanda S., Kufe D.;
RT   "Functional interaction between SHPTP1 and the Lyn tyrosine kinase in the
RT   apoptotic response to DNA damage.";
RL   J. Biol. Chem. 274:34663-34668(1999).
RN   [16]
RP   INTERACTION WITH CBLC.
RX   PubMed=10362357; DOI=10.1038/sj.onc.1202753;
RA   Keane M.M., Ettenberg S.A., Nau M.M., Banerjee P., Cuello M., Penninger J.,
RA   Lipkowitz S.;
RT   "cbl-3: a new mammalian cbl family protein.";
RL   Oncogene 18:3365-3375(1999).
RN   [17]
RP   FUNCTION IN CD79A PHOSPHORYLATION, AND INTERACTION WITH CD79A.
RX   PubMed=10748115; DOI=10.1074/jbc.m909044199;
RA   Gaul B.S., Harrison M.L., Geahlen R.L., Burton R.A., Post C.B.;
RT   "Substrate recognition by the Lyn protein-tyrosine kinase. NMR structure of
RT   the immunoreceptor tyrosine-based activation motif signaling region of the
RT   B cell antigen receptor.";
RL   J. Biol. Chem. 275:16174-16182(2000).
RN   [18]
RP   FUNCTION IN REGULATION OF MAST CELL PROLIFERATION, AND MUTAGENESIS OF
RP   LYS-275.
RX   PubMed=11435302; DOI=10.1182/blood.v98.2.343;
RA   O'Laughlin-Bunner B., Radosevic N., Taylor M.L., Shivakrupa R., DeBerry C.,
RA   Metcalfe D.D., Zhou M., Lowell C., Linnekin D.;
RT   "Lyn is required for normal stem cell factor-induced proliferation and
RT   chemotaxis of primary hematopoietic cells.";
RL   Blood 98:343-350(2001).
RN   [19]
RP   INTERACTION WITH PDE4A.
RC   TISSUE=Brain;
RX   PubMed=11306681; DOI=10.1124/mol.59.5.996;
RA   Rena G., Begg F., Ross A., MacKenzie C., McPhee I., Campbell L., Huston E.,
RA   Sullivan M., Houslay M.D.;
RT   "Molecular cloning, genomic positioning, promoter identification, and
RT   characterization of the novel cyclic AMP-specific phosphodiesterase
RT   PDE4A10.";
RL   Mol. Pharmacol. 59:996-1011(2001).
RN   [20]
RP   FUNCTION.
RX   PubMed=10891478; DOI=10.1128/mcb.20.15.5370-5380.2000;
RA   Yoshida K., Weichselbaum R., Kharbanda S., Kufe D.;
RT   "Role for Lyn tyrosine kinase as a regulator of stress-activated protein
RT   kinase activity in response to DNA damage.";
RL   Mol. Cell. Biol. 20:5370-5380(2000).
RN   [21]
RP   FUNCTION IN DNA DAMAGE RESPONSE; APOPTOSIS AND PHOSPHORYLATION OF PPP1R15A,
RP   INTERACTION WITH PPP1R15A, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-275.
RX   PubMed=11517336; DOI=10.1073/pnas.191130798;
RA   Grishin A.V., Azhipa O., Semenov I., Corey S.J.;
RT   "Interaction between growth arrest-DNA damage protein 34 and Src kinase Lyn
RT   negatively regulates genotoxic apoptosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:10172-10177(2001).
RN   [22]
RP   FUNCTION IN PHOSPHORYLATION OF KIT AND DOK1, CATALYTIC ACTIVITY, AND
RP   INTERACTION WITH KIT.
RX   PubMed=11825908; DOI=10.1074/jbc.m200277200;
RA   Liang X., Wisniewski D., Strife A., Shivakrupa R., Clarkson B., Resh M.D.;
RT   "Phosphatidylinositol 3-kinase and Src family kinases are required for
RT   phosphorylation and membrane recruitment of Dok-1 in c-Kit signaling.";
RL   J. Biol. Chem. 277:13732-13738(2002).
RN   [23]
RP   INTERACTION WITH MUC1.
RX   PubMed=12750561; DOI=10.4161/cbt.2.2.282;
RA   Li Y., Chen W., Ren J., Yu W.H., Li Q., Yoshida K., Kufe D.;
RT   "DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-
RT   7.";
RL   Cancer Biol. Ther. 2:187-193(2003).
RN   [24]
RP   INTERACTION WITH UNC119.
RX   PubMed=12496276; DOI=10.1074/jbc.m208261200;
RA   Cen O., Gorska M.M., Stafford S.J., Sur S., Alam R.;
RT   "Identification of UNC119 as a novel activator of SRC-type tyrosine
RT   kinases.";
RL   J. Biol. Chem. 278:8837-8845(2003).
RN   [25]
RP   FUNCTION IN THPO-MEDIATED CELL PROLIFERATION.
RX   PubMed=14726379; DOI=10.1182/blood-2003-10-3566;
RA   Lannutti B.J., Drachman J.G.;
RT   "Lyn tyrosine kinase regulates thrombopoietin-induced proliferation of
RT   hematopoietic cell lines and primary megakaryocytic progenitors.";
RL   Blood 103:3736-3743(2004).
RN   [26]
RP   SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF LYS-275; ASP-346; GLU-353;
RP   ASP-498 AND ASP-499.
RX   PubMed=15173188; DOI=10.1083/jcb.200403011;
RA   Kasahara K., Nakayama Y., Ikeda K., Fukushima Y., Matsuda D., Horimoto S.,
RA   Yamaguchi N.;
RT   "Trafficking of Lyn through the Golgi caveolin involves the charged
RT   residues on alphaE and alphaI helices in the kinase domain.";
RL   J. Cell Biol. 165:641-652(2004).
RN   [27]
RP   REVIEW ON ROLE IN KIT SIGNALING.
RX   PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055;
RA   Roskoski R. Jr.;
RT   "Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.";
RL   Biochem. Biophys. Res. Commun. 337:1-13(2005).
RN   [28]
RP   FUNCTION IN PHOSPHORYLATION OF HCLS1.
RX   PubMed=15795233; DOI=10.1074/jbc.m412634200;
RA   Brunati A.M., Deana R., Folda A., Massimino M.L., Marin O., Ledro S.,
RA   Pinna L.A., Donella-Deana A.;
RT   "Thrombin-induced tyrosine phosphorylation of HS1 in human platelets is
RT   sequentially catalyzed by Syk and Lyn tyrosine kinases and associated with
RT   the cellular migration of the protein.";
RL   J. Biol. Chem. 280:21029-21035(2005).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-508, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [30]
RP   FUNCTION.
RX   PubMed=16467205; DOI=10.1182/blood-2005-08-3343;
RA   Nakata Y., Tomkowicz B., Gewirtz A.M., Ptasznik A.;
RT   "Integrin inhibition through Lyn-dependent cross talk from CXCR4 chemokine
RT   receptors in normal human CD34+ marrow cells.";
RL   Blood 107:4234-4239(2006).
RN   [31]
RP   INTERACTION WITH ABL1.
RX   PubMed=16912036; DOI=10.1074/jbc.m605902200;
RA   Meyn M.A. III, Wilson M.B., Abdi F.A., Fahey N., Schiavone A.P., Wu J.,
RA   Hochrein J.M., Engen J.R., Smithgall T.E.;
RT   "Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate
RT   Bcr-Abl transforming activity.";
RL   J. Biol. Chem. 281:30907-30916(2006).
RN   [32]
RP   INTERACTION WITH PAG1, MUTAGENESIS OF TYR-397 AND TYR-508, ACTIVITY
RP   REGULATION, AND UBIQUITINATION.
RX   PubMed=16920712; DOI=10.1074/jbc.m602637200;
RA   Ingley E., Schneider J.R., Payne C.J., McCarthy D.J., Harder K.W.,
RA   Hibbs M.L., Klinken S.P.;
RT   "Csk-binding protein mediates sequential enzymatic down-regulation and
RT   degradation of Lyn in erythropoietin-stimulated cells.";
RL   J. Biol. Chem. 281:31920-31929(2006).
RN   [33]
RP   INTERACTION WITH TGFB1I1.
RX   PubMed=17233630; DOI=10.1042/bj20061618;
RA   Rathore V.B., Okada M., Newman P.J., Newman D.K.;
RT   "Paxillin family members function as Csk-binding proteins that regulate Lyn
RT   activity in human and murine platelets.";
RL   Biochem. J. 403:275-281(2007).
RN   [34]
RP   FUNCTION IN PHOSPHORYLATION OF LPXN, AND INTERACTION WITH LPXN.
RX   PubMed=17640867; DOI=10.1074/jbc.m704625200;
RA   Chew V., Lam K.P.;
RT   "Leupaxin negatively regulates B cell receptor signaling.";
RL   J. Biol. Chem. 282:27181-27191(2007).
RN   [35]
RP   INTERACTION WITH TOM1L1, AND FUNCTION IN TOM1L1 PHOSPHORYLATION.
RX   PubMed=17977829; DOI=10.1074/jbc.m705168200;
RA   Zhang J., Suzuki K., Hitomi T., Siraganian R.P.;
RT   "TOM1L1 is a Lyn substrate involved in FcepsilonRI signaling in mast
RT   cells.";
RL   J. Biol. Chem. 282:37669-37677(2007).
RN   [36]
RP   FUNCTION IN CELL PROLIFERATION AND SURVIVAL, PHOSPHORYLATION, SUBCELLULAR
RP   LOCATION, AND ROLE IN DISEASE.
RX   PubMed=18056483; DOI=10.1182/blood-2007-04-082099;
RA   Dos Santos C., Demur C., Bardet V., Prade-Houdellier N., Payrastre B.,
RA   Recher C.;
RT   "A critical role for Lyn in acute myeloid leukemia.";
RL   Blood 111:2269-2279(2008).
RN   [37]
RP   FUNCTION, PHOSPHORYLATION AT TYR-397 AND TYR-508, INTERACTION WITH PAG1 AND
RP   STAT3, AND SUBCELLULAR LOCATION.
RX   PubMed=18070987; DOI=10.1182/blood-2007-05-090985;
RA   Tauzin S., Ding H., Khatib K., Ahmad I., Burdevet D.,
RA   van Echten-Deckert G., Lindquist J.A., Schraven B., Din N.U., Borisch B.,
RA   Hoessli D.C.;
RT   "Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine
RT   kinase in human B-NHL rafts.";
RL   Blood 111:2310-2320(2008).
RN   [38]
RP   INTERACTION WITH CBL AND BCR-ABL, FUNCTION IN PHOSPHORYLATION OF BCR-ABL,
RP   AND ROLE IN DISEASE.
RX   PubMed=18235045; DOI=10.1182/blood-2007-08-109330;
RA   Wu J., Meng F., Lu H., Kong L., Bornmann W., Peng Z., Talpaz M.,
RA   Donato N.J.;
RT   "Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein
RT   stability in imatinib-resistant chronic myelogenous leukemia cells.";
RL   Blood 111:3821-3829(2008).
RN   [39]
RP   SUBCELLULAR LOCATION, MYRISTOYLATION AT GLY-2, PALMITOYLATION AT CYS-3, AND
RP   MUTAGENESIS OF GLY-2; CYS-3 AND LYS-275.
RX   PubMed=18817770; DOI=10.1016/j.yexcr.2008.08.019;
RA   Ikeda K., Nakayama Y., Togashi Y., Obata Y., Kuga T., Kasahara K.,
RA   Fukumoto Y., Yamaguchi N.;
RT   "Nuclear localization of Lyn tyrosine kinase mediated by inhibition of its
RT   kinase activity.";
RL   Exp. Cell Res. 314:3392-3404(2008).
RN   [40]
RP   FUNCTION IN ADHESION AND CELL MIGRATION.
RX   PubMed=18802065; DOI=10.4049/jimmunol.181.7.4632;
RA   Malik M., Chen Y.-Y., Kienzle M.F., Tomkowicz B.E., Collman R.G.,
RA   Ptasznik A.;
RT   "Monocyte migration and LFA-1-mediated attachment to brain microvascular
RT   endothelia is regulated by SDF-1 alpha through Lyn kinase.";
RL   J. Immunol. 181:4632-4637(2008).
RN   [41]
RP   PHOSPHORYLATION AT TYR-193 AND TYR-460, AND ROLE IN DISEASE.
RX   PubMed=18577747; DOI=10.1093/jnci/djn188;
RA   Wu J., Meng F., Kong L.Y., Peng Z., Ying Y., Bornmann W.G., Darnay B.G.,
RA   Lamothe B., Sun H., Talpaz M., Donato N.J.;
RT   "Association between imatinib-resistant BCR-ABL mutation-negative leukemia
RT   and persistent activation of LYN kinase.";
RL   J. Natl. Cancer Inst. 100:926-939(2008).
RN   [42]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11; SER-13; TYR-473 AND
RP   TYR-508, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [44]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [45]
RP   INTERACTION WITH FASLG.
RX   PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA   Voss M., Lettau M., Janssen O.;
RT   "Identification of SH3 domain interaction partners of human FasL (CD178) by
RT   phage display screening.";
RL   BMC Immunol. 10:53-53(2009).
RN   [46]
RP   INTERACTION WITH ADAM15.
RX   PubMed=19718658; DOI=10.1002/jcb.22317;
RA   Kleino I., Ortiz R.M., Yritys M., Huovila A.P., Saksela K.;
RT   "Alternative splicing of ADAM15 regulates its interactions with cellular
RT   SH3 proteins.";
RL   J. Cell. Biochem. 108:877-885(2009).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11; SER-13; SER-228; TYR-306;
RP   TYR-316; TYR-473 AND TYR-508, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [48]
RP   FUNCTION IN LTR4 AND LTR6 HETERODIMERIZATION, AND INTERACTION WITH CD36.
RX   PubMed=20037584; DOI=10.1038/ni.1836;
RA   Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J., Halle A.,
RA   Rayner K.J., Boyer L., Zhong R., Frazier W.A., Lacy-Hulbert A.,
RA   El Khoury J., Golenbock D.T., Moore K.J.;
RT   "CD36 ligands promote sterile inflammation through assembly of a Toll-like
RT   receptor 4 and 6 heterodimer.";
RL   Nat. Immunol. 11:155-161(2010).
RN   [49]
RP   INTERACTION WITH NDFIP1 AND NDFIP2, AND UBIQUITINATION.
RX   PubMed=20534535; DOI=10.1073/pnas.0911714107;
RA   Mund T., Pelham H.R.;
RT   "Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin
RT   ligase activators Ndfip1 and Ndfip2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [51]
RP   INTERACTION WITH SCIMP.
RX   PubMed=21930792; DOI=10.1128/mcb.05817-11;
RA   Draber P., Vonkova I., Stepanek O., Hrdinka M., Kucova M., Skopcova T.,
RA   Otahal P., Angelisova P., Horejsi V., Yeung M., Weiss A., Brdicka T.;
RT   "SCIMP, a transmembrane adapter protein involved in major
RT   histocompatibility complex class II signaling.";
RL   Mol. Cell. Biol. 31:4550-4562(2011).
RN   [52]
RP   REVIEW.
RX   PubMed=15220000; DOI=10.1016/j.molimm.2004.04.010;
RA   Lowell C.A.;
RT   "Src-family kinases: rheostats of immune cell signaling.";
RL   Mol. Immunol. 41:631-643(2004).
RN   [53]
RP   REVIEW ON ROLE IN B CELLS.
RX   PubMed=15489917; DOI=10.1038/sj.onc.1208075;
RA   Gauld S.B., Cambier J.C.;
RT   "Src-family kinases in B-cell development and signaling.";
RL   Oncogene 23:8001-8006(2004).
RN   [54]
RP   REVIEW ON ROLE IN B CELLS.
RX   PubMed=15664155; DOI=10.1016/j.immuni.2004.12.004;
RA   Xu Y., Harder K.W., Huntington N.D., Hibbs M.L., Tarlinton D.M.;
RT   "Lyn tyrosine kinase: accentuating the positive and the negative.";
RL   Immunity 22:9-18(2005).
RN   [55]
RP   REVIEW ON ROLE IN GROWTH FACTOR SIGNALING.
RX   PubMed=16801133; DOI=10.1080/08977190600581327;
RA   Hibbs M.L., Harder K.W.;
RT   "The duplicitous nature of the Lyn tyrosine kinase in growth factor
RT   signaling.";
RL   Growth Factors 24:137-149(2006).
RN   [56]
RP   REVIEW ON ROLE IN MAST CELLS.
RX   PubMed=18772004; DOI=10.1016/s0065-2776(08)00403-3;
RA   Rivera J., Fierro N.A., Olivera A., Suzuki R.;
RT   "New insights on mast cell activation via the high affinity receptor for
RT   IgE.";
RL   Adv. Immunol. 98:85-120(2008).
RN   [57]
RP   ROLE IN MYELOID CELL FUNCTION, AND SIGNALING.
RX   PubMed=19290919; DOI=10.1111/j.1600-065x.2008.00758.x;
RA   Scapini P., Pereira S., Zhang H., Lowell C.A.;
RT   "Multiple roles of Lyn kinase in myeloid cell signaling and function.";
RL   Immunol. Rev. 228:23-40(2009).
RN   [58]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11 AND SER-13, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [59]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11 AND SER-13, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [60]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11 AND SER-13, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [61]
RP   MYRISTOYLATION AT GLY-2, CLEAVAGE OF INITIATOR METHIONINE, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=25255805; DOI=10.1038/ncomms5919;
RA   Thinon E., Serwa R.A., Broncel M., Brannigan J.A., Brassat U., Wright M.H.,
RA   Heal W.P., Wilkinson A.J., Mann D.J., Tate E.W.;
RT   "Global profiling of co- and post-translationally N-myristoylated proteomes
RT   in human cells.";
RL   Nat. Commun. 5:4919-4919(2014).
RN   [62]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [63]
RP   STRUCTURE BY NMR OF 61-123 IN COMPLEX WITH SAIMIRIINE HERPESVIRUS 2
RP   TYROSINE KINASE INTERACTING PROTEIN (MICROBIAL INFECTION).
RX   PubMed=11955060; DOI=10.1021/bi015986j;
RA   Schweimer K., Hoffmann S., Bauer F., Friedrich U., Kardinal C.,
RA   Feller S.M., Biesinger B., Sticht H.;
RT   "Structural investigation of the binding of a herpesviral protein to the
RT   SH3 domain of tyrosine kinase Lck.";
RL   Biochemistry 41:5120-5130(2002).
RN   [64]
RP   STRUCTURE BY NMR OF 61-122, AND INTERACTION WITH HERPESVIRUS TYROSINE
RP   KINASE INTERACTING PROTEIN (MICROBIAL INFECTION).
RX   PubMed=16155203; DOI=10.1110/ps.051563605;
RA   Bauer F., Schweimer K., Meiselbach H., Hoffmann S., Rosch P., Sticht H.;
RT   "Structural characterization of Lyn-SH3 domain in complex with a
RT   herpesviral protein reveals an extended recognition motif that enhances
RT   binding affinity.";
RL   Protein Sci. 14:2487-2498(2005).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 233-512 IN COMPLEX WITH
RP   STAUROSPORINE.
RX   PubMed=19857964; DOI=10.1016/j.bmcl.2009.10.038;
RA   Miyano N., Kinoshita T., Nakai R., Kirii Y., Yokota K., Tada T.;
RT   "Structural basis for the inhibitor recognition of human Lyn kinase
RT   domain.";
RL   Bioorg. Med. Chem. Lett. 19:6557-6560(2009).
RN   [66]
RP   VARIANT [LARGE SCALE ANALYSIS] TYR-385.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine-protein kinase that transmits signals
CC       from cell surface receptors and plays an important role in the
CC       regulation of innate and adaptive immune responses, hematopoiesis,
CC       responses to growth factors and cytokines, integrin signaling, but also
CC       responses to DNA damage and genotoxic agents. Functions primarily as
CC       negative regulator, but can also function as activator, depending on
CC       the context. Required for the initiation of the B-cell response, but
CC       also for its down-regulation and termination. Plays an important role
CC       in the regulation of B-cell differentiation, proliferation, survival
CC       and apoptosis, and is important for immune self-tolerance. Acts
CC       downstream of several immune receptors, including the B-cell receptor,
CC       CD79A, CD79B, CD5, CD19, CD22, FCER1, FCGR2, FCGR1A, TLR2 and TLR4.
CC       Plays a role in the inflammatory response to bacterial
CC       lipopolysaccharide. Mediates the responses to cytokines and growth
CC       factors in hematopoietic progenitors, platelets, erythrocytes, and in
CC       mature myeloid cells, such as dendritic cells, neutrophils and
CC       eosinophils. Acts downstream of EPOR, KIT, MPL, the chemokine receptor
CC       CXCR4, as well as the receptors for IL3, IL5 and CSF2. Plays an
CC       important role in integrin signaling. Regulates cell proliferation,
CC       survival, differentiation, migration, adhesion, degranulation, and
CC       cytokine release. Down-regulates signaling pathways by phosphorylation
CC       of immunoreceptor tyrosine-based inhibitory motifs (ITIM), that then
CC       serve as binding sites for phosphatases, such as PTPN6/SHP-1,
CC       PTPN11/SHP-2 and INPP5D/SHIP-1, that modulate signaling by
CC       dephosphorylation of kinases and their substrates. Phosphorylates LIME1
CC       in response to CD22 activation. Phosphorylates BTK, CBL, CD5, CD19,
CC       CD72, CD79A, CD79B, CSF2RB, DOK1, HCLS1, LILRB3/PIR-B, MS4A2/FCER1B,
CC       SYK and TEC. Promotes phosphorylation of SIRPA, PTPN6/SHP-1,
CC       PTPN11/SHP-2 and INPP5D/SHIP-1. Mediates phosphorylation of the BCR-ABL
CC       fusion protein. Required for rapid phosphorylation of FER in response
CC       to FCER1 activation. Mediates KIT phosphorylation. Acts as an effector
CC       of EPOR (erythropoietin receptor) in controlling KIT expression and may
CC       play a role in erythroid differentiation during the switch between
CC       proliferation and maturation. Depending on the context, activates or
CC       inhibits several signaling cascades. Regulates phosphatidylinositol 3-
CC       kinase activity and AKT1 activation. Regulates activation of the MAP
CC       kinase signaling cascade, including activation of MAP2K1/MEK1,
CC       MAPK1/ERK2, MAPK3/ERK1, MAPK8/JNK1 and MAPK9/JNK2. Mediates activation
CC       of STAT5A and/or STAT5B. Phosphorylates LPXN on 'Tyr-72'. Kinase
CC       activity facilitates TLR4-TLR6 heterodimerization and signal
CC       initiation. Phosphorylates SCIMP on 'Tyr-107'; this enhances binding of
CC       SCIMP to TLR4, promoting the phosphorylation of TLR4, and a selective
CC       cytokine response to lipopolysaccharide in macrophages (By similarity).
CC       Phosphorylates CLNK (By similarity). Phosphorylates BCAR1/CAS and
CC       NEDD9/HEF1 (PubMed:9020138). {ECO:0000250|UniProtKB:P25911,
CC       ECO:0000269|PubMed:10574931, ECO:0000269|PubMed:10748115,
CC       ECO:0000269|PubMed:10891478, ECO:0000269|PubMed:11435302,
CC       ECO:0000269|PubMed:11517336, ECO:0000269|PubMed:11825908,
CC       ECO:0000269|PubMed:14726379, ECO:0000269|PubMed:15795233,
CC       ECO:0000269|PubMed:16467205, ECO:0000269|PubMed:17640867,
CC       ECO:0000269|PubMed:17977829, ECO:0000269|PubMed:18056483,
CC       ECO:0000269|PubMed:18070987, ECO:0000269|PubMed:18235045,
CC       ECO:0000269|PubMed:18577747, ECO:0000269|PubMed:18802065,
CC       ECO:0000269|PubMed:19290919, ECO:0000269|PubMed:20037584,
CC       ECO:0000269|PubMed:7687428, ECO:0000269|PubMed:9020138}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:11517336, ECO:0000269|PubMed:11825908,
CC         ECO:0000269|PubMed:7682714, ECO:0000269|PubMed:8064233};
CC   -!- ACTIVITY REGULATION: Subject to autoinhibition, mediated by
CC       intramolecular interactions between the SH2 domain and the C-terminal
CC       phosphotyrosine. Phosphorylation at Tyr-397 is required for optimal
CC       activity. Phosphorylated by CSK at Tyr-508; phosphorylation at Tyr-508
CC       inhibits kinase activity. Kinase activity is modulated by
CC       dephosphorylation by PTPRC/CD45. Inhibited by Dasatinib, PP2, and
CC       SU6656. {ECO:0000269|PubMed:16920712, ECO:0000269|PubMed:7935444}.
CC   -!- SUBUNIT: Interacts with TEC. Interacts (via SH2 domain) with FLT3
CC       (tyrosine phosphorylated). Interacts with LIME1 and with CD79A upon
CC       activation of the B-cell antigen receptor. Interacts with the B-cell
CC       receptor complex. Interacts with phosphorylated THEMIS2. Interacts with
CC       EPOR. Interacts with MS4A2/FCER1B. Interaction (via the SH2 and SH3
CC       domains) with MUC1 is stimulated by IL7 and the subsequent
CC       phosphorylation increases the binding between MUC1 and CTNNB1/beta-
CC       catenin. Interacts with ADAM15. Interacts with NDFIP2 and more weakly
CC       with NDFIP1. Interacts with FASLG. Interacts with KIT. Interacts with
CC       HCLS1. Interacts with FCGR2B. Interacts with FCGR1A; the interaction
CC       may be indirect. Interacts with CD19, CD22, CD79A and CD79B. Interacts
CC       (via SH3 domain) with CBLC, PPP1R15A and PDE4A. Interacts with TGFB1I1.
CC       Interacts (via SH3 domain) with PIK3R1, the regulatory subunit of
CC       phosphatidylinositol 3-kinase; this interaction enhances
CC       phosphatidylinositol 3-kinase activity. Interacts with CSF2RB, the
CC       common subunit of the IL3, IL5 and CSF2 receptors. Interacts with PAG1;
CC       identified in a complex with PAG1 and STAT3. Interacts with ABL1.
CC       Interacts with PTPN6/SHP-1. Interacts (via SH3 domain) with SCIMP (via
CC       proline-rich region) (PubMed:21930792). This interaction facilitates
CC       the phosphorylation of SCIMP on 'Tyr-107', which enhances binding of
CC       SCIMP to TLR4, and consequently the phosphorylation of TLR4 in response
CC       to stimulation by lipopolysaccharide in macrophages (By similarity).
CC       Interacts with LPXN (via LD motif 3) and the interaction is induced
CC       upon B-cell antigen receptor (BCR) activation. Interacts (via SH3-
CC       domain) with ANKRD54 (via ankyrin repeat region) in an activation-
CC       independent status of LYN. Forms a multiprotein complex with ANKRD54
CC       and HCLS1. Interacts (via SH2 and SH3 domains) with UNC119; leading to
CC       LYN activation. Interacts with CD36. Interacts with LYN (By
CC       similarity). Interacts with SKAP1 and FYB1; this interaction promotes
CC       the phosphorylation of CLNK (By similarity). Interacts with BCAR1/CAS
CC       and NEDD9/HEF1 (PubMed:9020138). {ECO:0000250|UniProtKB:P25911,
CC       ECO:0000269|PubMed:10362357, ECO:0000269|PubMed:10574931,
CC       ECO:0000269|PubMed:10748115, ECO:0000269|PubMed:11306681,
CC       ECO:0000269|PubMed:11517336, ECO:0000269|PubMed:11825908,
CC       ECO:0000269|PubMed:12496276, ECO:0000269|PubMed:12750561,
CC       ECO:0000269|PubMed:16912036, ECO:0000269|PubMed:16920712,
CC       ECO:0000269|PubMed:17233630, ECO:0000269|PubMed:17640867,
CC       ECO:0000269|PubMed:17977829, ECO:0000269|PubMed:18070987,
CC       ECO:0000269|PubMed:18235045, ECO:0000269|PubMed:19718658,
CC       ECO:0000269|PubMed:19807924, ECO:0000269|PubMed:19857964,
CC       ECO:0000269|PubMed:20037584, ECO:0000269|PubMed:20534535,
CC       ECO:0000269|PubMed:21930792, ECO:0000269|PubMed:7682714,
CC       ECO:0000269|PubMed:7687428, ECO:0000269|PubMed:8064233,
CC       ECO:0000269|PubMed:9020138, ECO:0000269|PubMed:9232445,
CC       ECO:0000269|PubMed:9341198}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Epstein-Barr virus LMP2A.
CC       {ECO:0000269|PubMed:7895172}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Herpes virus saimiri
CC       tyrosine kinase interacting protein (Tip).
CC       {ECO:0000269|PubMed:11955060, ECO:0000269|PubMed:16155203}.
CC   -!- INTERACTION:
CC       P07948; P01023: A2M; NbExp=3; IntAct=EBI-79452, EBI-640741;
CC       P07948; O43184: ADAM12; NbExp=2; IntAct=EBI-79452, EBI-2625825;
CC       P07948; Q13444: ADAM15; NbExp=2; IntAct=EBI-79452, EBI-77818;
CC       P07948; P05067: APP; NbExp=3; IntAct=EBI-79452, EBI-77613;
CC       P07948; P10275: AR; NbExp=5; IntAct=EBI-79452, EBI-608057;
CC       P07948; Q8NDB2: BANK1; NbExp=3; IntAct=EBI-79452, EBI-2837677;
CC       P07948; Q96GW7: BCAN; NbExp=3; IntAct=EBI-79452, EBI-2690445;
CC       P07948; P20273: CD22; NbExp=2; IntAct=EBI-79452, EBI-78277;
CC       P07948; P25063: CD24; NbExp=6; IntAct=EBI-79452, EBI-6267018;
CC       P07948; P16671: CD36; NbExp=3; IntAct=EBI-79452, EBI-2808214;
CC       P07948; P11049: CD37; NbExp=5; IntAct=EBI-79452, EBI-6139068;
CC       P07948; P46527: CDKN1B; NbExp=2; IntAct=EBI-79452, EBI-519280;
CC       P07948; P50570-2: DNM2; NbExp=3; IntAct=EBI-79452, EBI-10968534;
CC       P07948; P00533: EGFR; NbExp=7; IntAct=EBI-79452, EBI-297353;
CC       P07948; Q9BS26: ERP44; NbExp=3; IntAct=EBI-79452, EBI-541644;
CC       P07948; Q13480: GAB1; NbExp=7; IntAct=EBI-79452, EBI-517684;
CC       P07948; Q9HCN6: GP6; NbExp=5; IntAct=EBI-79452, EBI-515278;
CC       P07948; Q9HCN6-1: GP6; NbExp=2; IntAct=EBI-79452, EBI-15816577;
CC       P07948; P08238: HSP90AB1; NbExp=2; IntAct=EBI-79452, EBI-352572;
CC       P07948; P05556: ITGB1; NbExp=4; IntAct=EBI-79452, EBI-703066;
CC       P07948; P10721: KIT; NbExp=7; IntAct=EBI-79452, EBI-1379503;
CC       P07948; Q96L34: MARK4; NbExp=3; IntAct=EBI-79452, EBI-302319;
CC       P07948; P33993: MCM7; NbExp=4; IntAct=EBI-79452, EBI-355924;
CC       P07948; P51608: MECP2; NbExp=3; IntAct=EBI-79452, EBI-1189067;
CC       P07948; P08581: MET; NbExp=2; IntAct=EBI-79452, EBI-1039152;
CC       P07948; Q9NWQ8: PAG1; NbExp=16; IntAct=EBI-79452, EBI-2828115;
CC       P07948; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-79452, EBI-9090282;
CC       P07948; P07602: PSAP; NbExp=3; IntAct=EBI-79452, EBI-716699;
CC       P07948; P63244: RACK1; NbExp=2; IntAct=EBI-79452, EBI-296739;
CC       P07948; Q6UWF3: SCIMP; NbExp=3; IntAct=EBI-79452, EBI-2872510;
CC       P07948; P37840: SNCA; NbExp=3; IntAct=EBI-79452, EBI-985879;
CC       P07948; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-79452, EBI-5235340;
CC       P07948; P12931: SRC; NbExp=4; IntAct=EBI-79452, EBI-621482;
CC       P07948; Q8R5G7: Arap3; Xeno; NbExp=2; IntAct=EBI-79452, EBI-621463;
CC       P07948; Q08857: Cd36; Xeno; NbExp=2; IntAct=EBI-79452, EBI-8346984;
CC       P07948; O92972; Xeno; NbExp=2; IntAct=EBI-79452, EBI-710506;
CC       P07948; P22575; Xeno; NbExp=3; IntAct=EBI-79452, EBI-866709;
CC       P07948; P27958; Xeno; NbExp=4; IntAct=EBI-79452, EBI-706378;
CC       P07948; Q9WMX2; Xeno; NbExp=3; IntAct=EBI-79452, EBI-710918;
CC       P07948-1; P00533: EGFR; NbExp=2; IntAct=EBI-6895930, EBI-297353;
CC       P07948-1; P33993: MCM7; NbExp=5; IntAct=EBI-6895930, EBI-355924;
CC   -!- SUBCELLULAR LOCATION: Cell membrane. Nucleus. Cytoplasm. Cytoplasm,
CC       perinuclear region. Golgi apparatus. Membrane {ECO:0000305}; Lipid-
CC       anchor {ECO:0000305}. Note=Accumulates in the nucleus by inhibition of
CC       CRM1-mediated nuclear export. Nuclear accumulation is increased by
CC       inhibition of its kinase activity. The trafficking from the Golgi
CC       apparatus to the plasma membrane occurs in a kinase domain-dependent
CC       but kinase activity independent manner and is mediated by exocytic
CC       vesicular transport. Detected on plasma membrane lipid rafts.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=LYN A, p56lyn;
CC         IsoId=P07948-1; Sequence=Displayed;
CC       Name=2; Synonyms=LYN B, p53lyn;
CC         IsoId=P07948-2; Sequence=VSP_005002;
CC   -!- TISSUE SPECIFICITY: Detected in monocytes (at protein level). Detected
CC       in placenta, and in fetal brain, lung, liver and kidney. Widely
CC       expressed in a variety of organs, tissues, and cell types such as
CC       epidermoid, hematopoietic, and neuronal cells. Expressed in primary
CC       neuroblastoma tumors. {ECO:0000269|PubMed:3561390,
CC       ECO:0000269|PubMed:8064233}.
CC   -!- DOMAIN: The protein kinase domain plays an important role in its
CC       localization in the cell membrane. {ECO:0000269|PubMed:15173188}.
CC   -!- PTM: Ubiquitinated by CBL, leading to its degradation. Ubiquitination
CC       is SH3-dependent. {ECO:0000269|PubMed:16920712,
CC       ECO:0000269|PubMed:20534535}.
CC   -!- PTM: Autophosphorylated (PubMed:7935444, PubMed:9171348,
CC       PubMed:9341198, PubMed:18056483, PubMed:18070987). Phosphorylated on
CC       tyrosine residues in response to KIT signaling (PubMed:9341198).
CC       Phosphorylation at Tyr-397 is required for optimal activity
CC       (PubMed:16920712). Phosphorylation at Tyr-508 inhibits kinase activity
CC       (PubMed:9171348). Phosphorylated at Tyr-508 by CSK (PubMed:7935444).
CC       Dephosphorylated by PTPRC/CD45 (By similarity). Becomes rapidly
CC       phosphorylated upon activation of the B-cell receptor and the
CC       immunoglobulin receptor FCGR1A (PubMed:8064233). Phosphorylated in
CC       response to ITGB1 in B-cells (PubMed:9020138).
CC       {ECO:0000250|UniProtKB:P25911, ECO:0000269|PubMed:16920712,
CC       ECO:0000269|PubMed:18056483, ECO:0000269|PubMed:18070987,
CC       ECO:0000269|PubMed:7935444, ECO:0000269|PubMed:8064233,
CC       ECO:0000269|PubMed:9020138, ECO:0000269|PubMed:9171348,
CC       ECO:0000269|PubMed:9341198}.
CC   -!- DISEASE: Note=Constitutively phosphorylated and activated in cells from
CC       a number of chronic myelogenous leukemia (CML) and acute myeloid
CC       leukemia (AML) patients. Mediates phosphorylation of the BCR-ABL fusion
CC       protein. Abnormally elevated expression levels or activation of LYN
CC       signaling may play a role in survival and proliferation of some types
CC       of cancer cells.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SRC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M16038; AAA59540.1; -; mRNA.
DR   EMBL; M79321; AAB50019.1; -; mRNA.
DR   EMBL; BC075001; AAH75001.1; -; mRNA.
DR   EMBL; BC075002; AAH75002.1; -; mRNA.
DR   EMBL; BC126456; AAI26457.1; -; mRNA.
DR   EMBL; BC126458; AAI26459.1; -; mRNA.
DR   CCDS; CCDS47859.1; -. [P07948-2]
DR   CCDS; CCDS6162.1; -. [P07948-1]
DR   PIR; A26719; TVHULY.
DR   RefSeq; NP_001104567.1; NM_001111097.2. [P07948-2]
DR   RefSeq; NP_002341.1; NM_002350.3. [P07948-1]
DR   RefSeq; XP_016868905.1; XM_017013416.1. [P07948-2]
DR   PDB; 1W1F; NMR; -; A=61-123.
DR   PDB; 1WA7; NMR; -; A=61-123.
DR   PDB; 3A4O; X-ray; 3.00 A; X=233-512.
DR   PDB; 5XY1; X-ray; 2.70 A; A=239-512.
DR   PDB; 6NMW; X-ray; 1.20 A; A=63-125.
DR   PDBsum; 1W1F; -.
DR   PDBsum; 1WA7; -.
DR   PDBsum; 3A4O; -.
DR   PDBsum; 5XY1; -.
DR   PDBsum; 6NMW; -.
DR   AlphaFoldDB; P07948; -.
DR   BMRB; P07948; -.
DR   SMR; P07948; -.
DR   BioGRID; 110245; 696.
DR   CORUM; P07948; -.
DR   DIP; DIP-1056N; -.
DR   ELM; P07948; -.
DR   IntAct; P07948; 143.
DR   MINT; P07948; -.
DR   STRING; 9606.ENSP00000428924; -.
DR   BindingDB; P07948; -.
DR   ChEMBL; CHEMBL3905; -.
DR   DrugBank; DB03023; 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine.
DR   DrugBank; DB06616; Bosutinib.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugCentral; P07948; -.
DR   GuidetoPHARMACOLOGY; 2060; -.
DR   iPTMnet; P07948; -.
DR   PhosphoSitePlus; P07948; -.
DR   SwissPalm; P07948; -.
DR   BioMuta; LYN; -.
DR   DMDM; 125480; -.
DR   REPRODUCTION-2DPAGE; P07948; -.
DR   CPTAC; CPTAC-2785; -.
DR   EPD; P07948; -.
DR   jPOST; P07948; -.
DR   MassIVE; P07948; -.
DR   MaxQB; P07948; -.
DR   PaxDb; P07948; -.
DR   PeptideAtlas; P07948; -.
DR   PRIDE; P07948; -.
DR   ProteomicsDB; 52045; -. [P07948-1]
DR   ProteomicsDB; 52046; -. [P07948-2]
DR   Antibodypedia; 51187; 919 antibodies from 44 providers.
DR   DNASU; 4067; -.
DR   Ensembl; ENST00000519728.6; ENSP00000428924.1; ENSG00000254087.8. [P07948-1]
DR   Ensembl; ENST00000520220.6; ENSP00000428424.1; ENSG00000254087.8. [P07948-2]
DR   GeneID; 4067; -.
DR   KEGG; hsa:4067; -.
DR   MANE-Select; ENST00000519728.6; ENSP00000428924.1; NM_002350.4; NP_002341.1.
DR   UCSC; uc003xsk.5; human. [P07948-1]
DR   CTD; 4067; -.
DR   DisGeNET; 4067; -.
DR   GeneCards; LYN; -.
DR   HGNC; HGNC:6735; LYN.
DR   HPA; ENSG00000254087; Tissue enhanced (bone marrow, lymphoid tissue).
DR   MIM; 165120; gene.
DR   neXtProt; NX_P07948; -.
DR   OpenTargets; ENSG00000254087; -.
DR   PharmGKB; PA30498; -.
DR   VEuPathDB; HostDB:ENSG00000254087; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   GeneTree; ENSGT00940000158011; -.
DR   HOGENOM; CLU_000288_7_2_1; -.
DR   InParanoid; P07948; -.
DR   OMA; PKAQRPW; -.
DR   OrthoDB; 597979at2759; -.
DR   PhylomeDB; P07948; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; P07948; -.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-2029481; FCGR activation.
DR   Reactome; R-HSA-210990; PECAM1 interactions.
DR   Reactome; R-HSA-2454202; Fc epsilon receptor (FCERI) signaling.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-HSA-2871837; FCERI mediated NF-kB activation.
DR   Reactome; R-HSA-389356; CD28 co-stimulation.
DR   Reactome; R-HSA-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   Reactome; R-HSA-5621480; Dectin-2 family.
DR   Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-HSA-5690714; CD22 mediated BCR regulation.
DR   Reactome; R-HSA-69231; Cyclin D associated events in G1.
DR   Reactome; R-HSA-75892; Platelet Adhesion to exposed collagen.
DR   Reactome; R-HSA-9006335; Signaling by Erythropoietin.
DR   Reactome; R-HSA-9027276; Erythropoietin activates Phosphoinositide-3-kinase (PI3K).
DR   Reactome; R-HSA-9027277; Erythropoietin activates Phospholipase C gamma (PLCG).
DR   Reactome; R-HSA-9027283; Erythropoietin activates STAT5.
DR   Reactome; R-HSA-9027284; Erythropoietin activates RAS.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   Reactome; R-HSA-9664323; FCGR3A-mediated IL10 synthesis.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants.
DR   Reactome; R-HSA-9674555; Signaling by CSF3 (G-CSF).
DR   Reactome; R-HSA-9705462; Inactivation of CSF3 (G-CSF) signaling.
DR   Reactome; R-HSA-982772; Growth hormone receptor signaling.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; P07948; -.
DR   SIGNOR; P07948; -.
DR   BioGRID-ORCS; 4067; 12 hits in 1120 CRISPR screens.
DR   ChiTaRS; LYN; human.
DR   EvolutionaryTrace; P07948; -.
DR   GeneWiki; LYN; -.
DR   GenomeRNAi; 4067; -.
DR   Pharos; P07948; Tclin.
DR   PRO; PR:P07948; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; P07948; protein.
DR   Bgee; ENSG00000254087; Expressed in monocyte and 187 other tissues.
DR   ExpressionAtlas; P07948; baseline and differential.
DR   Genevisible; P07948; HS.
DR   GO; GO:0005912; C:adherens junction; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0034666; C:integrin alpha2-beta1 complex; IEA:Ensembl.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005765; C:lysosomal membrane; TAS:Reactome.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0030061; C:mitochondrial crista; IEA:Ensembl.
DR   GO; GO:0005758; C:mitochondrial intermembrane space; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0099091; C:postsynaptic specialization, intracellular component; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0046875; F:ephrin receptor binding; IPI:ARUK-UCL.
DR   GO; GO:0043015; F:gamma-tubulin binding; IEA:Ensembl.
DR   GO; GO:0043208; F:glycosphingolipid binding; IEA:Ensembl.
DR   GO; GO:0005178; F:integrin binding; IEA:Ensembl.
DR   GO; GO:0016301; F:kinase activity; NAS:ARUK-UCL.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IMP:ARUK-UCL.
DR   GO; GO:0051219; F:phosphoprotein binding; IEA:Ensembl.
DR   GO; GO:0140031; F:phosphorylation-dependent protein binding; IPI:UniProtKB.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; IEA:Ensembl.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:ARUK-UCL.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:Ensembl.
DR   GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central.
DR   GO; GO:0044325; F:transmembrane transporter binding; IPI:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0001782; P:B cell homeostasis; ISS:UniProtKB.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0038159; P:C-X-C chemokine receptor CXCR4 signaling pathway; IMP:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0031668; P:cellular response to extracellular stimulus; IEA:Ensembl.
DR   GO; GO:0034605; P:cellular response to heat; IEA:Ensembl.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL.
DR   GO; GO:0097028; P:dendritic cell differentiation; ISS:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0030218; P:erythrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0002774; P:Fc receptor mediated inhibitory signaling pathway; ISS:UniProtKB.
DR   GO; GO:0002431; P:Fc receptor mediated stimulatory signaling pathway; ISS:UniProtKB.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0060397; P:growth hormone receptor signaling pathway via JAK-STAT; TAS:Reactome.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IMP:UniProtKB.
DR   GO; GO:0002553; P:histamine secretion by mast cell; IEA:Ensembl.
DR   GO; GO:0002768; P:immune response-regulating cell surface receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:Ensembl.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0030889; P:negative regulation of B cell proliferation; IBA:GO_Central.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0050777; P:negative regulation of immune response; TAS:UniProtKB.
DR   GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; TAS:Reactome.
DR   GO; GO:1902532; P:negative regulation of intracellular signal transduction; ISS:UniProtKB.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:0070667; P:negative regulation of mast cell proliferation; ISS:UniProtKB.
DR   GO; GO:0002762; P:negative regulation of myeloid leukocyte differentiation; IEA:Ensembl.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0034136; P:negative regulation of toll-like receptor 2 signaling pathway; ISS:UniProtKB.
DR   GO; GO:0034144; P:negative regulation of toll-like receptor 4 signaling pathway; ISS:UniProtKB.
DR   GO; GO:0031175; P:neuron projection development; IBA:GO_Central.
DR   GO; GO:0014003; P:oligodendrocyte development; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0002576; P:platelet degranulation; ISS:UniProtKB.
DR   GO; GO:1902961; P:positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process; IMP:ARUK-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:UniProtKB.
DR   GO; GO:2000670; P:positive regulation of dendritic cell apoptotic process; ISS:UniProtKB.
DR   GO; GO:0060369; P:positive regulation of Fc receptor mediated stimulatory signaling pathway; IEA:Ensembl.
DR   GO; GO:0060252; P:positive regulation of glial cell proliferation; IEA:Ensembl.
DR   GO; GO:0070668; P:positive regulation of mast cell proliferation; IMP:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL.
DR   GO; GO:0070447; P:positive regulation of oligodendrocyte progenitor proliferation; IEA:Ensembl.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IEA:Ensembl.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IGI:ARUK-UCL.
DR   GO; GO:0070304; P:positive regulation of stress-activated protein kinase signaling cascade; IDA:UniProtKB.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0002902; P:regulation of B cell apoptotic process; IBA:GO_Central.
DR   GO; GO:0050855; P:regulation of B cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0033628; P:regulation of cell adhesion mediated by integrin; IMP:UniProtKB.
DR   GO; GO:0001817; P:regulation of cytokine production; ISS:UniProtKB.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0045646; P:regulation of erythrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0033003; P:regulation of mast cell activation; ISS:UniProtKB.
DR   GO; GO:0043304; P:regulation of mast cell degranulation; ISS:UniProtKB.
DR   GO; GO:0090025; P:regulation of monocyte chemotaxis; IMP:UniProtKB.
DR   GO; GO:0090330; P:regulation of platelet aggregation; ISS:UniProtKB.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; TAS:UniProtKB.
DR   GO; GO:0051279; P:regulation of release of sequestered calcium ion into cytosol; IEA:Ensembl.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0048678; P:response to axon injury; IEA:Ensembl.
DR   GO; GO:0009743; P:response to carbohydrate; IEA:Ensembl.
DR   GO; GO:0009725; P:response to hormone; ISS:UniProtKB.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0006991; P:response to sterol depletion; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0002513; P:tolerance induction to self antigen; ISS:UniProtKB.
DR   GO; GO:0034142; P:toll-like receptor 4 signaling pathway; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IMP:UniProtKB.
DR   CDD; cd10364; SH2_Src_Lyn; 1.
DR   CDD; cd12004; SH3_Lyn; 1.
DR   DisProt; DP02545; -.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR035852; Lyn_SH2.
DR   InterPro; IPR035748; Lyn_SH3.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; ATP-binding;
KW   Cell membrane; Cytoplasm; Golgi apparatus; Host-virus interaction;
KW   Immunity; Inflammatory response; Innate immunity; Kinase; Lipoprotein;
KW   Membrane; Myristate; Nucleotide-binding; Nucleus; Palmitate;
KW   Phosphoprotein; Proto-oncogene; Reference proteome; SH2 domain; SH3 domain;
KW   Transferase; Tyrosine-protein kinase; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:25255805"
FT   CHAIN           2..512
FT                   /note="Tyrosine-protein kinase Lyn"
FT                   /id="PRO_0000088129"
FT   DOMAIN          63..123
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          129..226
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          247..501
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..62
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        23..55
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        367
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         253..261
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         275
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         11
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         13
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         193
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:18577747"
FT   MOD_RES         228
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         306
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         316
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         397
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18070987,
FT                   ECO:0000269|PubMed:7935444"
FT   MOD_RES         460
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:18577747"
FT   MOD_RES         473
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         508
FT                   /note="Phosphotyrosine; by autocatalysis, CSK and MATK"
FT                   /evidence="ECO:0000269|PubMed:18070987,
FT                   ECO:0000269|PubMed:7935444, ECO:0000269|PubMed:9171348,
FT                   ECO:0007744|PubMed:15592455, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   LIPID           2
FT                   /note="N-myristoyl glycine"
FT                   /evidence="ECO:0000269|PubMed:25255805,
FT                   ECO:0000305|PubMed:18817770"
FT   LIPID           3
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000305|PubMed:18817770"
FT   VAR_SEQ         23..43
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:8125304"
FT                   /id="VSP_005002"
FT   VARIANT         385
FT                   /note="D -> Y (in a breast pleomorphic lobular carcinoma
FT                   sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041737"
FT   MUTAGEN         2
FT                   /note="G->A: Loss of localization to the cell membrane;
FT                   when associated with A-3."
FT                   /evidence="ECO:0000269|PubMed:18817770"
FT   MUTAGEN         3
FT                   /note="C->A: Loss of localization to the cell membrane;
FT                   when associated with A-2."
FT                   /evidence="ECO:0000269|PubMed:18817770"
FT   MUTAGEN         275
FT                   /note="K->A: Loss of activity and no effect on localization
FT                   to the cell membrane. Abundant localization in the nucleus;
FT                   when associated with A-2 and A-3."
FT                   /evidence="ECO:0000269|PubMed:11435302,
FT                   ECO:0000269|PubMed:11517336, ECO:0000269|PubMed:15173188,
FT                   ECO:0000269|PubMed:18817770"
FT   MUTAGEN         275
FT                   /note="K->L,R: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:11435302,
FT                   ECO:0000269|PubMed:11517336, ECO:0000269|PubMed:15173188,
FT                   ECO:0000269|PubMed:18817770"
FT   MUTAGEN         346
FT                   /note="D->A: Impedes the trafficking from the Golgi
FT                   apparatus toward the cell membrane; when associated with
FT                   A-353; A-498 and A-499."
FT                   /evidence="ECO:0000269|PubMed:15173188"
FT   MUTAGEN         353
FT                   /note="E->A: Impedes the trafficking from the Golgi
FT                   apparatus toward the cell membrane; when associated with
FT                   A-346; A-498 and A-499."
FT                   /evidence="ECO:0000269|PubMed:15173188"
FT   MUTAGEN         397
FT                   /note="Y->F: Strongly reduced kinase activity."
FT                   /evidence="ECO:0000269|PubMed:16920712"
FT   MUTAGEN         498
FT                   /note="D->A: Impedes the trafficking from the Golgi
FT                   apparatus toward the cell membrane; when associated with
FT                   A-346; A-353 and A-499."
FT                   /evidence="ECO:0000269|PubMed:15173188"
FT   MUTAGEN         499
FT                   /note="D->A: Impedes the trafficking from the Golgi
FT                   apparatus toward the cell membrane; when associated with
FT                   A-346; A-353 and A-498."
FT                   /evidence="ECO:0000269|PubMed:15173188"
FT   MUTAGEN         508
FT                   /note="Y->F: Abolishes autoinhibition and thereby increases
FT                   kinase activity."
FT                   /evidence="ECO:0000269|PubMed:16920712"
FT   STRAND          67..72
FT                   /evidence="ECO:0007829|PDB:6NMW"
FT   STRAND          78..80
FT                   /evidence="ECO:0007829|PDB:1W1F"
FT   STRAND          89..96
FT                   /evidence="ECO:0007829|PDB:6NMW"
FT   STRAND          99..104
FT                   /evidence="ECO:0007829|PDB:6NMW"
FT   TURN            105..107
FT                   /evidence="ECO:0007829|PDB:6NMW"
FT   STRAND          110..114
FT                   /evidence="ECO:0007829|PDB:6NMW"
FT   HELIX           115..117
FT                   /evidence="ECO:0007829|PDB:6NMW"
FT   STRAND          118..121
FT                   /evidence="ECO:0007829|PDB:6NMW"
FT   HELIX           244..246
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   STRAND          247..255
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   STRAND          260..266
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   TURN            267..269
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   STRAND          270..277
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   HELIX           284..296
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   STRAND          305..309
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   STRAND          311..320
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   HELIX           327..332
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   HELIX           334..338
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   HELIX           341..360
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   HELIX           370..372
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   STRAND          373..375
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   STRAND          381..383
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   HELIX           407..409
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   HELIX           412..417
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   HELIX           422..437
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   HELIX           449..457
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   STRAND          466..468
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   HELIX           470..479
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   HELIX           484..486
FT                   /evidence="ECO:0007829|PDB:5XY1"
FT   HELIX           490..501
FT                   /evidence="ECO:0007829|PDB:5XY1"
SQ   SEQUENCE   512 AA;  58574 MW;  408D3D461204E378 CRC64;
     MGCIKSKGKD SLSDDGVDLK TQPVRNTERT IYVRDPTSNK QQRPVPESQL LPGQRFQTKD
     PEEQGDIVVA LYPYDGIHPD DLSFKKGEKM KVLEEHGEWW KAKSLLTKKE GFIPSNYVAK
     LNTLETEEWF FKDITRKDAE RQLLAPGNSA GAFLIRESET LKGSFSLSVR DFDPVHGDVI
     KHYKIRSLDN GGYYISPRIT FPCISDMIKH YQKQADGLCR RLEKACISPK PQKPWDKDAW
     EIPRESIKLV KRLGAGQFGE VWMGYYNNST KVAVKTLKPG TMSVQAFLEE ANLMKTLQHD
     KLVRLYAVVT REEPIYIITE YMAKGSLLDF LKSDEGGKVL LPKLIDFSAQ IAEGMAYIER
     KNYIHRDLRA ANVLVSESLM CKIADFGLAR VIEDNEYTAR EGAKFPIKWT APEAINFGCF
     TIKSDVWSFG ILLYEIVTYG KIPYPGRTNA DVMTALSQGY RMPRVENCPD ELYDIMKMCW
     KEKAEERPTF DYLQSVLDDF YTATEGQYQQ QP
//
